Search our team at AdventHealth Research Institute
-
NCT5812807
Optimice-PCR: De-Escalation Of Therapy In Early-Stage TNBC Patients Who Achieve PCR After Neoadjuvant Chemotherapy With Checkpoint Inhibitor Therapy
This study is currently enrolling.Associated Conditions: Breast CancerResearch Area: Cancer ResearchResearch Location: Orlando, FloridaThis study is being done to answer the following question: Among patients with early-stage TNBC who achieve a pCR after preoperative chemotherapy in combination with pembrolizumab, will observation...
-
NCT05382286
A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician’s Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced, Inoperable, or Metastatic Triple-Negative Breast Cancer, Whose Tumors Express PD-L1.
This study is currently enrolling.Associated Conditions: Breast CancerResearch Area: Cancer ResearchResearch Location: Altamonte, FloridaThe purpose of this study is to see if sacituzumab govitecan in combination with pembrolizumab can improve lifespans of patients with advanced, PD-L1 positive TNBC and their tumor does not grow or...
-
NCT05812807
OptimICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy
This study is not currently enrolling.Associated Conditions: Breast CancerResearch Area: Cancer ResearchTo evaluate whether observation results in a non-inferior RFS compared to adjuvant pembrolizumab in early-stage TNBC patients who achieve a pCR after neoadjuvant chemotherapy with pembrolizumab
-
NCT05840211
A Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Patients with Hormone Receptor-Positive (HR+)/Human Epidermal Growth Factor Receptor 2-Negative (HER2−) (HER2 IHC0 or HER2-low [IHC 1+, IHC 2+/ISH−]) Inoperable, Locally Advanced, or Metastatic Breast Cancer and Have Received Endocrine Therapy ASCENT 07
This study is not currently enrolling.Associated Conditions: Breast CancerResearch Area: Cancer ResearchResearch Location: Altamonte, FloridaThe purpose of this study is to see if sacituzumab govitecan can improve life spans of patients with HR+/HER2- metastatic breast cancer and their tumor does not grow or spread when compared to current...